Our goal is to treat the second-degree and third-degree burn wounds. It is expected to reduce
antibiotic use and form a barrier that can prevent wound infection by P. aeruginosa.
Throughout
the
project, we realized that much work remained to be done and that experimental data are further
needed to
support the entire project. In the future, we will still continue to improve the design and
construction
to achieve our goals.
However, we believe that our work is a considerable contribution to the iGEM community. In general,
our
future work will be focused in four aspects, including 1.the antipseudomonal drug synthesis module,
2.the
c-di-GMP signaling and BC film production module, 3. integration, 4. product.
● Antipseudomonal drug synthesis module
At present, we have successfully introduced the drug production module containing SE- and
IMM-encoded
genes into Gluconacetobacter hansenii ATCC 53582. At the same time, the
Pseudomonas-specificity and
antibacterial effect of SE protein expressed with different RBS were verified.
In addition, to have a persistent resistance of SE to Pseudomonas aeruginosa, we are
engineering
an
anchor protein, which can enhance the attachment of the anti-pseudomonal drug SE to the BC film
produced
by G. hansenii ATCC 53582.
● C-di-GMP signaling and BC film production module
In the c-di-GMP signaling and BC film production module, our previous expectation is that the film
would
be produced under near-infrared light, but not under the dark conditions. In our experiments, we
firstly
verified that the BphS protein can increase the film production by Gluconacetobacter hansenii
ATCC 53582
under near-infrared light conditions. Then the bphS was engineered to integrate together with yhjH
and
fcsR parts that can hydrolyze c-di-GMP, and a few engineered bacteria were screened for better film
growth under NIR light exposure than under dark conditions, but we have not yet managed to make
engineered bacteria not grow BC films under dark conditions.
To solve this problem, we will make the following two adjustments in the future:
1. Re-screen the parts that can hydrolyze c-di-GMP.
2. Modulate the BphS expression level or the strength of yhjH and fcsR to achieve the purpose that BC film can be produced under near-infrared light irradiation, but not under dark conditions.
To solve this problem, we will make the following two adjustments in the future:
1. Re-screen the parts that can hydrolyze c-di-GMP.
2. Modulate the BphS expression level or the strength of yhjH and fcsR to achieve the purpose that BC film can be produced under near-infrared light irradiation, but not under dark conditions.
● Integration
The goal of the whole project is to engineer a bacterium that can produce BC film under
near-infrared
light, but not under dark conditions. While treated by the blue light, the engineered bacterium
would be
lysed with the release of the antibacterial drugs. Then the antibacterial drugs SE are bound to BC
film.
In this year, we have individually verified the function of three modules, but have not yet
integrated
all of three modules into Gluconacetobacter hansenii ATCC 53582. So, it remains to verify
whether these
modules can operate normally if they are combined together. These will be our major work in the
future.
● Product
In our product form, the set expectation is to make live bacteria lyophilizer and an oil-in-water
system
emulsion. We have made great success in the emulsion part, while the survival rate of live bacteria
in
the lyophilizer is about 20%, which has not reached our expectation. To improve bacterial survival
rate
in our products, we will continue to search the literature, and identify better agents and
conditions to
lyophilize G. hansenii ATCC 53582 in the future.